DataLibraryResearch is tracking the market dynamics of the crisis in the Pharma & Healthcare industry amid lock-down changes in the supply chain.

Get detailed analysis of the COVID-19 impact on the Viral Vector And Plasmid DNA Manufacturing Market

Global Viral Vector And Plasmid DNA Manufacturing Market Opportunities and Forecast 2020-2027

  • DLR2702
  • 02 August, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Viral Vector And Plasmid DNA Manufacturing Market, By Product (Plasmid DNA, Viral Vectors, Non-Viral Vectors), By Workflow (Upstream Processing, Downstream Processing), By Disease (Cancer, Inherited Disorders, Viral Infections, Others), By Application (Antisense, Rnai, & Molecular Therapy And Vaccinology), By Sales Channel (Channel Sales And Direct Sales), By End User (Pharmaceutical And Biopharmaceutical Companies And Research Institutes Cancer) And Opportunities And Forecast 2020-2027.

Viral Vector and Plasmid DNA Manufacturing Market Overview

The global Viral Vector and Plasmid DNA Manufacturing market is expected to grow at a moderate rate during the forecast period. Increasing burden of viral infections globally has resulted in the high demand for viral vector and DNA manufacturing, which is acting as a stimulating factor for the market growth. According to the article published in BMC infectious disease in February 2021, viral infection such as respiratory syncytial virus (RSV) is reported to be one of the leading cause of acute lower respiratory illness (ALRI) in infants and children.

Furthermore, increasing number of clinical trials is accelerating inclination for viral vectors in gene transfer. As a result, investors are attracted towards this area which is making plasmid and viral vector manufacturing market a vigorous sector of investment.

On the other hand, High manufacturing cost associated with the manufacturing of viral vector and plasmid

DNA is likely to hamper the global Viral Vector and Plasmid DNA Manufacturing market during the forecast period.

Covid-19 Impact on Viral Vector and Plasmid DNA Manufacturing Market:

In addition, the current Viral Vector and Plasmid DNA Manufacturing Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Viral Vector and Plasmid DNA Manufacturing Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.

Viral Vector and Plasmid DNA Manufacturing Market Segment Overview

According to Product types, the market is segmented into Plasmid DNA, Viral Vectors,  Non-Viral Vectors. Among these Viral Vectors holds the largest share of the market as its most powerful means of transmitting genes to change particular types of cells or tissues. It is used  For the treatment of different ailments such as cardiovascular, muscular, metabolic, haematological, ophthalmological, and infectious diseases and various types of cancer.

According to Workflow, the market is segmented into Upstream Processing, Downstream Processing. Among these Upstream Processing holds the largest share of the market.  

On the basis of Disease types, the market is segmented into Cancer, Inherited Disorders, Viral Infections, Others. Among these cancer segment holds the highest market share as Cancer is the world's second leading cause of death, responsible for an estimated 9.6 million fatalities in 2018, or one in six deaths

On the basis of Application, the market is segmented into Antisense, Rnai, & Molecular Therapy And Vaccinology. Among these Anti-sense, RNAi & Molecular Therapy segment holds the highest market share as it has become a major tool in the investigation of gene function.

Based on Sales Channel, the market is segmented into Channel Sales And Direct Sales. Among these Anti-sense, Channel Sales segment holds the highest market share as it’s the highest adopted method for sales by pharma and biotechnology companies.

Based on End User, the market is segmented into Pharmaceutical And Biopharmaceutical Companies And Research Institutes Cancer. Among these Pharmaceutical And Biopharmaceutical Companies segment holds the highest market share.

Market Analysis, Insights and Forecast – By Product

·       Plasmid DNA
·       Viral Vectors
·       Non-Viral Vectors

Market Analysis, Insights and Forecast – By Workflow  

·       Upstream Processing
·       Downstream Processing

Market Analysis, Insights, and Forecast – By Disease

·       Cancer
·       Inherited Disorders
·       Viral Infections
·       Others

Market Analysis, Insights, and Forecast – By Application

·       Antisense, Rnai, & Molecular Therapy
·       Vaccinology

Market Analysis, Insights, and Forecast – By Sales Channel

·       Channel Sales
·       Direct Sales

Market Analysis, Insights, and Forecast – By End-user

·       Pharmaceutical And Biopharmaceutical Companies
·       Research Institutes Cancer

Viral Vector and Plasmid DNA Manufacturing Market Regional Overview

The regional analysis include adoption of Hospital Beds products across North America, Europe, Asia-Pacific (APAC), Latin America Middle East & Africa (MEA). Among these North America dominated the global Viral Vector and Plasmid DNA Manufacturing market. Factors such as the growing prevalence of new cancer cases, and high health care expenditure propels the growth of the market in North America. Similarly, Asia Pacific is also expected to account for the fastest growth in the global market owing to well-established health care infrastructure. Factors such as increasing government and public spending health budget and global investments coming up in health related research and development, it is imperative to state that investments should increase in global viral vector and plasma DNA manufacturing market..

Viral Vector and Plasmid DNA Manufacturing Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)

Viral Vector and Plasmid DNA Manufacturing Market Competitor overview

Some key developments and strategies adopted by manufacturers in the Viral Vector and Plasmid DNA Manufacturing are highlighted below.

·       In January 2021, Thermo Fisher Scientific Inc. acquired Henogen S.A., Novasep's viral vector manufacturing business in Belgium for approximately €725 million in cash. 

Viral Vector and Plasmid DNA Manufacturing Market, Key Players

·       FUJIFILM Diosynth Biotechnologies
·       Kaneka Eurogentec S.A
·       FinVector
·       Spark Therapeutics
·       Cobra Biologics
·       Cell and Gene Therapy Catapult
·       Renova Therapeutics
·       Shenzhen SiBiono GeneTech Co., Ltd.
·       4D Molecular Therapeutics
·       Thermo Fisher Scientific, Inc.

Viral Vector and Plasmid DNA Manufacturing Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Product
        • 5.2.1. Plasmid DNA
        • 5.2.2. Viral Vectors
        • 5.2.3. Non-Viral Vectors
      • 5.3. Market Analysis, Insights and Forecast – By Workflow
        • 5.3.1. Upstream Processing
        • 5.3.2. Downstream Processing
      • 5.4. Market Analysis, Insights, and Forecast – By Disease
        • 5.4.1. Cancer
        • 5.4.2. Inherited Disorders
        • 5.4.3. Viral Infections
        • 5.4.4. Others
      • 5.5. Market Analysis, Insights, and Forecast – By Application
        • 5.5.1. Antisense, Rnai, & Molecular Therapy
        • 5.5.2. Vaccinology
      • 5.6. Market Analysis, Insights, and Forecast – By Sales Channel
        • 5.6.1. Channel Sales
        • 5.6.2. Direct Sales
      • 5.7. Market Analysis, Insights, and Forecast – By End-user
        • 5.7.1. Pharmaceutical And Biopharmaceutical Companies
        • 5.7.2. Research Institutes Cancer
      • 5.8. Market Analysis, Insights and Forecast – By Region
        • 5.8.1. North America
        • 5.8.2. Europe
        • 5.8.3. Asia Pacific
        • 5.8.4. Latin America, Middle East, and Africa

      6. North America Viral Vector and Plasmid DNA Manufacturing Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Product
        • 6.2.1. Plasmid DNA
        • 6.2.2. Viral Vectors
        • 6.2.3. Non-Viral Vectors
      • 6.3. Market Analysis, Insights and Forecast – By Workflow
        • 6.3.1. Upstream Processing
        • 6.3.2. Downstream Processing
      • 6.4. Market Analysis, Insights, and Forecast – By Disease
        • 6.4.1. Cancer
        • 6.4.2. Inherited Disorders
        • 6.4.3. Viral Infections
        • 6.4.4. Others
      • 6.5. Market Analysis, Insights, and Forecast – By Application
        • 6.5.1. Antisense, Rnai, & Molecular Therapy
        • 6.5.2. Vaccinology
      • 6.6. Market Analysis, Insights, and Forecast – By Sales Channel
        • 6.6.1. Channel Sales
        • 6.6.2. Direct Sales
      • 6.7. Market Analysis, Insights, and Forecast – By End-user
        • 6.7.1. Pharmaceutical And Biopharmaceutical Companies
        • 6.7.2. Research Institutes Cancer
      • 6.8. Market Analysis, Insights and Forecast – By Country
        • 6.8.1. U.S.
        • 6.8.2. Canada

      7. Europe Viral Vector and Plasmid DNA Manufacturing Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Product
        • 7.2.1. Plasmid DNA
        • 7.2.2. Viral Vectors
        • 7.2.3. Non-Viral Vectors
      • 7.3. Market Analysis, Insights and Forecast – By Workflow
        • 7.3.1. Upstream Processing
        • 7.3.2. Downstream Processing
      • 7.4. Market Analysis, Insights, and Forecast – By Disease
        • 7.4.1. Cancer
        • 7.4.2. Inherited Disorders
        • 7.4.3. Viral Infections
        • 7.4.4. Others
      • 7.5. Market Analysis, Insights, and Forecast – By Application
        • 7.5.1. Antisense, Rnai, & Molecular Therapy
        • 7.5.2. Vaccinology
      • 7.6. Market Analysis, Insights, and Forecast – By Sales Channel
        • 7.6.1. Channel Sales
        • 7.6.2. Direct Sales
      • 7.7. Market Analysis, Insights, and Forecast – By End-user
        • 7.7.1. Pharmaceutical And Biopharmaceutical Companies
        • 7.7.2. Research Institutes Cancer
      • 7.8. Market Analysis, Insights and Forecast – By Country
        • 7.8.1. UK
        • 7.8.2. Germany
        • 7.8.3. France
        • 7.8.4. Italy
        • 7.8.5. Spain
        • 7.8.6. Russia
        • 7.8.7. Rest of Europe

      8. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Product
        • 8.2.1. Plasmid DNA
        • 8.2.2. Viral Vectors
        • 8.2.3. Non-Viral Vectors
      • 8.3. Market Analysis, Insights and Forecast – By Workflow
        • 8.3.1. Upstream Processing
        • 8.3.2. Downstream Processing
      • 8.4. Market Analysis, Insights, and Forecast – By Disease
        • 8.4.1. Cancer
        • 8.4.2. Inherited Disorders
        • 8.4.3. Viral Infections
        • 8.4.4. Others
      • 8.5. Market Analysis, Insights, and Forecast – By Application
        • 8.5.1. Antisense, Rnai, & Molecular Therapy
        • 8.5.2. Vaccinology
      • 8.6. Market Analysis, Insights, and Forecast – By Sales Channel
        • 8.6.1. Channel Sales
        • 8.6.2. Direct Sales
      • 8.7. Market Analysis, Insights, and Forecast – By End-user
        • 8.7.1. Pharmaceutical And Biopharmaceutical Companies
        • 8.7.2. Research Institutes Cancer
      • 8.8. Market Analysis, Insights and Forecast – By Country
        • 8.8.1. China
        • 8.8.2. India
        • 8.8.3. Japan
        • 8.8.4. Australia
        • 8.8.5. South East Asia
        • 8.8.6. Rest of Asia Pacific

      9. Latin America, Middle East, and Africa Viral Vector and Plasmid DNA Manufacturing Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Product
        • 9.2.1. Plasmid DNA
        • 9.2.2. Viral Vectors
        • 9.2.3. Non-Viral Vectors
      • 9.3. Market Analysis, Insights and Forecast – By Workflow
        • 9.3.1. Upstream Processing
        • 9.3.2. Downstream Processing
      • 9.4. Market Analysis, Insights, and Forecast – By Disease
        • 9.4.1. Cancer
        • 9.4.2. Inherited Disorders
        • 9.4.3. Viral Infections
        • 9.4.4. Others
      • 9.5. Market Analysis, Insights, and Forecast – By Application
        • 9.5.1. Antisense, Rnai, & Molecular Therapy
        • 9.5.2. Vaccinology
      • 9.6. Market Analysis, Insights, and Forecast – By Sales Channel
        • 9.6.1. Channel Sales
        • 9.6.2. Direct Sales
      • 9.7. Market Analysis, Insights, and Forecast – By End-user
        • 9.7.1. Pharmaceutical And Biopharmaceutical Companies
        • 9.7.2. Research Institutes Cancer
      • 9.8. Market Analysis, Insights and Forecast – By Country
        • 9.8.1. Brazil
        • 9.8.2. Saudi Arabia
        • 9.8.3. UAE
        • 9.8.4. Rest of LAMEA

      10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. FUJIFILM Diosynth Biotechnologies
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. Kaneka Eurogentec S.A
      • 10.6. FinVector
      • 10.7. Spark Therapeutics
      • 10.8. Cobra Biologics
      • 10.9. Cell and Gene Therapy Catapult
      • 10.10. Renova Therapeutics
      • 10.11. Shenzhen SiBiono GeneTech Co., Ltd.
      • 10.12. 4D Molecular Therapeutics

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934